Jayawardhana Jayani, Hou Jialin, Freeman Patricia, Talbert Jeffery C
Department of Health Management and Policy, College of Public Health, University of Kentucky, Lexington.
Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington.
JAMA Psychiatry. 2025 Mar 1;82(3):228-236. doi: 10.1001/jamapsychiatry.2024.4145.
Whether state implementation of medical and recreational cannabis laws is associated with increased cannabis use disorder (CUD) and/or cannabis poisoning among adults is not evident.
To examine state-level medical and recreational cannabis laws' associations with CUD and cannabis poisoning, overall and by sex and age subgroups.
DESIGN, SETTING, AND PARTICIPANTS: In this longitudinal cohort study, state-level CUD and cannabis poisoning diagnoses from January 2011 to December 2021 were examined across all 50 US states and the District of Columbia before and after the implementation of medical and recreational cannabis laws (MCLs and RCLs, respectively) using a staggered adoption difference-in-differences approach. Event studies were conducted to estimate the magnitude of the association for each year-quarter relative to the time of each policy implementation. This study was conducted among all adults aged 18 to 64 years enrolled in the Merative MarketScan Commercial Claims and Encounters Database, a database of employer-sponsored health insurance enrollees, with 1 year or more of continuous enrollment from 2011 to 2021. Data analysis was performed from January to August 2024.
State implementation of an MCL, opening a medical cannabis dispensary (MCD), allowing home cultivation of medical cannabis (HC-MC), and passage of an RCL.
CUD and cannabis poisoning diagnoses per 100 000 enrollees per quarter.
This study included 110 256 536 enrollees, of whom 56 843 030 (52%) were female and the mean (SD) enrollee age was 41.0 (13.5) years. MCLs were associated with significant increases in CUD and cannabis poisoning by 31.09 (95% CI, 20.20-41.99; P < .001) and 0.76 (95% CI, 0.52-1.00; P < .001) diagnoses per 100 000 enrollees per quarter, respectively, and RCLs were associated with a significant increase in cannabis poisoning by 0.34 (95% CI, 0.19-0.48; P < .001) per 100 000 enrollees per quarter in states with RCLs compared to states without these laws. No significant associations were observed for MCDs or HC-MC. Relative increases in CUD associated with MCLs were higher among female enrollees and among enrollees aged 35 to 44 years compared with male enrollees and other age groups, respectively. Sensitivity analysis results of 2011 to 2019 data were consistent with the 2011 to 2021 results.
In this longitudinal cohort study, MCLs were associated with increased CUD and cannabis poisoning diagnoses, and RCLs were associated with increased cannabis poisoning in adults aged 18 to 64 years with employer-sponsored health insurance. Communities with increased access to cannabis may experience increased health care use and costs due to increases in cannabis poisoning and CUD, and new clinical and policy interventions are needed to curb these rising diagnoses.
各州实施医用和娱乐用大麻法律是否与成年人中大麻使用障碍(CUD)和/或大麻中毒增加相关尚不清楚。
研究各州层面的医用和娱乐用大麻法律与CUD及大麻中毒之间的关联,总体情况以及按性别和年龄亚组进行分析。
设计、背景和参与者:在这项纵向队列研究中,采用交错采用的差分法,对2011年1月至2021年12月期间美国50个州和哥伦比亚特区在实施医用和娱乐用大麻法律(分别为MCL和RCL)之前和之后的州级CUD和大麻中毒诊断情况进行了研究。进行事件研究以估计相对于每项政策实施时间的每年每季度的关联程度。本研究在所有年龄在18至64岁、纳入了艾美仕市场扫描商业理赔与诊疗数据库的成年人中开展,该数据库是一个雇主赞助的健康保险参保者数据库,这些参保者在2011年至2021年期间连续参保1年或更长时间。数据分析于2024年1月至8月进行。
州实施MCL、开设医用大麻药房(MCD)、允许家庭种植医用大麻(HC-MC)以及通过RCL。
每季度每10万名参保者中的CUD和大麻中毒诊断数。
本研究纳入了110256536名参保者,其中56843030名(52%)为女性,参保者的平均(标准差)年龄为41.0(13.5)岁。MCL与每季度每10万名参保者中CUD和大麻中毒诊断数显著增加相关,分别增加31.09(95%置信区间,20.20 - 41.99;P <.001)和0.76(95%置信区间,0.52 - 1.00;P <.001),与没有这些法律的州相比,RCL与有RCL的州每季度每10万名参保者中大麻中毒诊断数显著增加0.34(95%置信区间,0.19 - 0.48;P <.001)相关。未观察到MCD或HC-MC有显著关联。与MCL相关的CUD相对增加在女性参保者中以及在年龄为35至44岁的参保者中分别高于男性参保者和其他年龄组。2011年至2019年数据的敏感性分析结果与201年至2021年的结果一致。
在这项纵向队列研究中,MCL与CUD和大麻中毒诊断数增加相关,RCL与年龄在18至64岁且有雇主赞助健康保险的成年人中大麻中毒增加相关。大麻获取途径增加的社区可能因大麻中毒和CUD增加而导致医疗保健使用和成本增加,需要新的临床和政策干预措施来遏制这些不断上升的诊断数。